- Greenwich noted that despite the absence of a placebo arm, GLSI-100 showed an annual recurrence rate below 1%, compared with about 4% in the KATHERINE trial of Kadcyla over a similar timeframe.
- The company also stated that the Phase III trial results are trending in line with those from the Phase IIb trial.
- Greenwich reported a reduction of up to 80% in breast cancer recurrences, while other approved products showed a reduction of 20% to 25%, the company said.
Greenwich LifeSciences Inc. (GLSI) shares gained more than 13% in Tuesday’s pre-market trade after the company announced that its immunotherapy trial has shown a continued reduction in the rate of recurrence of breast cancer.
Greenwich LifeSciences said its 250-patient Phase III breast cancer immunotherapy trial, FLAMINGO-01, showed an annual recurrence rate below 1%.
Retail sentiment on Stocktwits around Greenwich LifeSciences trended in the ‘extremely bullish’ territory with message volumes at ‘extremely high’ levels. GLSI was the top trending ticker on the platform at the time of writing.
Results Show About 70-80% Reduction In Recurrence Rate, Says Greenwich
Greenwich noted that despite the absence of a placebo arm, GLSI-100 showed an annual recurrence rate below 1%, compared with about 4% in the KATHERINE trial of Kadcyla over a similar timeframe.
The company also stated that the results of the Phase III trial are trending in line with those from the Phase IIb results. Greenwich reported a reduction of up to 80% in breast cancer recurrences, while other approved products showed a reduction of 20% to 25%, the company said.
However, Greenwich stated that these Phase III trial results are still preliminary and that the final analysis may differ.
The Phase III FLAMINGO-01 trial is designed to evaluate the safety and efficacy of GLSI-100 in HER2-positive breast cancer patients with residual disease or high-risk pathological complete response who have completed neoadjuvant and adjuvant trastuzumab-based therapy.
What Does Greenwich LifeSciences Do?
Greenwich LifeSciences is a clinical-stage biopharmaceutical company based out of Stafford, Texas. It is currently focused on the development of GP2, which is an immunotherapy to prevent breast cancer recurrence in patients who have previously undergone surgery.
GLSI stock is up 34% year-to-date and 134% over the past 12 months. The iShares Russell 2000 Growth ETF (IWO) is up 22% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 40%.
Also See: Trump Says Fed Chair Powell Should Cut Rates Right Now
For updates and corrections, email newsroom[at]stocktwits[dot]com.